Clin Lab. 2026 Jun 1;72(3). doi: 10.7754/Clin.Lab.2025.250535.
ABSTRACT
BACKGROUND: Patients with myeloproliferative diseases have an increased risk and incidence of thrombotic complications. The mechanisms involved in the pathogenesis of this acquired thrombophilic state are multifactorial. One mechanism reported in the literature is increased thrombopoiesis and with it associated increase of young, immature platelets in peripheral blood. This increased washout of new platelets, which are unaffected by antiplatelet drugs, may lead to a reduced response to antiplatelet therapy.
METHODS: In our study, we aimed to monitor the efficacy of the standard of antiplatelet therapy with 100 mg of acetylsalicylic acid in relation to immature platelet size fraction and platelet count in a group of 86 patients with myeloproliferative diseases. The efficacy of antiplatelet therapy was investigated by the ASPItest method on the multiplate impedance aggregometer.
RESULTS: The results demonstrated that the efficacy of low-dose acetylsalicylic acid treatment was independent of immature platelet fraction size (0.2600, p = 0.0156) and absolute platelet count (0.4505, p < 0.0001). Detailed analysis of the cohort showed no association between the incidence of thrombotic complications and the ASPItest value, nor was there an association between the incidence of thrombotic complications and the size of the immature platelet fraction or the total platelet count.
CONCLUSIONS: The mechanisms not assessable by impedance aggregometry are involved in the development of thrombotic complications in patients with MPD; the value of the ASPItest does not provide comprehensive information about thrombotic risk.
PMID:41945742 | DOI:10.7754/Clin.Lab.2025.250535